Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Fernández-Laguna, Clara Luza; | Maray, Ivana | Macia-Rivas, Lolaa | Álvarez-Asteinza, Cristinaa | Fernández-Lastras, Sergioa | Velasco Durántez, Veronicab | Carbajales Álvarez, Mónicaa | Lozano-Blázquez, Anaa
Affiliations: [a] Department of Pharmacy, Hospital Universitario Central de Asturias, Oviedo, Spain | [b] Department of Oncology, Hospital Universitario de Cabueñes, Gijon, Spain
Correspondence: [*] Corresponding author: Clara Luz Fernández-Laguna, Department of Pharmacy, Hospital Universitario Central de Asturias. Av Roma s/n 33011, Oviedo, Spain. Tel.:+34 6525670990; E-mail: claraferlag@gmail.com. ORCID: https://orcid.org/0000-0001-5909-5639
Abstract: BACKGROUND:Metastatic breast cancer (MBC) is incurable. Systemic therapy is the standard treatment; however, an optimal sequence of chemotherapy has not been established. OBJECTIVE:Evaluating effectiveness and safety of eribulin in MBC treatment and comparing the results obtained with published literature. METHODS:Observational, descriptive and retrospective study of patients with MBC treated with eribulin from 01/12/2015 to 30/10/2021. Effectiveness was analysed using Kaplan–Meier-survival-curves, for the overall number of patients treated and stratified by treatment line. Safety was measured according to adverse events (AE) based on CTCAE v5.0. Data analysis was performed using R v4.0.1. RESULTS:They were included in this study 53 women who received eribulin (median age 58 years). Comparison of median survival from this study versus published data were: progression-free-survival (PFS) 3 (IC95%: 3–4) versus 3.7 months and overall-survival (OS) 8 (IC95%: 3–4) versus 13.2 months for the overall number of patients. For the 1–3 line treatment group, PFS was 6 (IC95%: 3-NA) and OS was 15 (IC95%: 6-NA). There were 322 AEs, the most frequent being blood disorders 16% (52), general disorders 12% (38), and gastrointestinal disorders 12% (38). CONCLUSIONS:The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.
Keywords: Eribulin, metastatic breast cancer, effectiveness, safety, Real world data
DOI: 10.3233/BD-230031
Journal: Breast Disease, vol. 42, no. 1, pp. 349-360, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl